admin,  —

Relapsing-remitting multiple sclerosis (RRMS) patients accurately report the use of the RebiSmart autoinjector to their neurologists, a questionnaire-based study has found. The Phase 4 noninterventional CORE study also suggests that being knowledgeable about RebiSmart is a key factor in improving usage in younger patients and those with lower disability levels.

MS patients who start treatment at a younger age, and whose condition requires hospitalization, are more likely to stop treatment, a Canadian study reports. The research, published in the journal Dovepress, dealt with the main reasons Canadian patients quit first-line injected disease-modifying therapies, or DMTs. It was titled “Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort.” DMTs can reduce MS activity, but patients must stick with them in order for them to be effective. “There is currently a paucity of clinical trial data on what happens to individuals when they discontinue DMT," the researchers wrote. "However, recent preliminary evidence from observational studies suggest increased relapses and disability in those who discontinue DMT." Researchers sought to identify MS patients at higher risk of discontinuing treatment. They looked at Manitoba Province's medical database to identify the types of drugs MS patients were taking, and for how long. The analysis covered 721 patients who received injected beta-interferons or Copaxone between 1996 and 2011, and whom doctors followed for at least a year. Teva manufactures Copaxone, whose generic name is glatiramer acetate. The mean age of the patients in the study was 37.6 years, and 74.2 percent were women. Researchers defined a discontinuation of a DMT as a 90-day or longer gap in treatment. A third of the patients were treated with beta-interferon-1b, either Bayer HealthCare's Betaferon/Betaseron or Novartis' Extavia. It was the first such therapy available in Manitoba. Twenty-three percent of patients received beta-interferon-1a, either Biogen's Avonex or Merck's Rebif. And 21 percent received Copaxone. The median time before a patient discontinued a DMT was 4.2 years. Although 62.6 percent of patients discontinued treatment at some point, 57.4 percent either reinitiated it or switched to a different DMT. Patients who were on DMT at least a year were more likely to stay with it than those who stopped in the first year. Importantly, patients who started a DMT at a younger age were more likely to stop taking it than older patients. “Our results are also consistent with previous work examining persistence for other chronic medication classes, including statins, antihypertensives, bisphosphonates, and oral antidiabetic agents, where the risk for discontinuing drugs declined in a linear fashion with age,” the researchers wrote. The team also found that 16 percent of patients had to be hospitalized overnight, with 3 percent of the cases due to MS-related complications. And these hospitalized patients were more likely to stop their DMT treatment earlier, the researchers said. Summing up, the team said: "Subjects who were younger when starting a DMT, had prior MS-related hospitalizations, were more recently diagnosed with MS, or had a greater lag time between their MS diagnosis and DMT initiation were more likely to discontinue therapy." Although "not all of the factors identified with discontinuing DMT" can be modified, "they may help practitioners enhance MS care by identifying individuals who may be at particular risk for DMT discontinuation," the researchers concluded.

A recent study has found Tysabri (natalizumab) treatment for two years to be efficient and safe in Japanese patients with relapsing-remitting multiple sclerosis (RRMS). The study, “Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial,” appeared in the journal…

It’s been less than a month since Ocrevus was approved by the FDA, and the buzz hasn’t died down. Though there is some trepidation, the MS community is incredibly excited about what the new “game-changing” medication can do for patients all across the country. Here are just a few…

Here’s my Pick of the Week’s News, as published by Multiple Sclerosis News Today. Canada, World’s Multiple Sclerosis Capital, Launches 3-Way Collaboration to Research MS Progression Why some people develop primary progressive MS and others have the relapsing type, and why a many relapsing patients develop secondary…

Ocrevus is a “fabulous” drug that does wonders for those who respond to it. That’s the view of an MS nurse practitioner in Florida, with whom I spoke this week. Tricia Pagnotta works at the Multiple Sclerosis…

Today, my Pick of the Week’s News is devoted to various news stories, all published by Multiple Sclerosis News Today, about FDA approval of Genentech’s Ocrevus as an MS treatment. FDA Approves Ocrevus as 1st MS Treatment for Both Relapsing and Primary Progressive Forms Last week’s approval of Ocrevus (ocrelizumab) by…

Caregivers are in the spotlight during MS Awareness Month and, as it draws to a close, one man with multiple sclerosis is calling for everyone with the disease to recognize them. Dan Melfi, who lives in the…

Mothers with chronic inflammatory and autoimmune diseases, such as multiple sclerosis, have a higher risk of having children with attention-deficit/hyperactivity disorder (ADHD), according to a Norwegian study. The findings were reported in a study titled “Attention-Deficit/Hyperactivity Disorder in Offspring of Mothers With Inflammatory and Immune System Diseases”…

Here’s my Pick of the Week’s News, as published in Multiple Sclerosis News Today. National MS Society-Sponsored Group Creates Tool Set to Measure Outcomes in MS Clinical Trials Speeding up clinical trials should have the knock-on effect of shortening the whole process of developing and approving new…

What is benign MS? Does it even exist? Certainly it is not one of the types of the disease often listed as making up the multiple sclerosis family. It is a term that is surrounded by controversy,…

Here is my Pick of the Week’s News, as published by Multiple Sclerosis News Today. Ocrevus and the hope of ‘ending MS forever’: Interview with MS Society’s Tim Coetzee Ocrevus possibly being one of the most significant advances in MS treatment, especially for people with PPMS, the…

News that daclizumab, brand name Zinbryta, has been given the go-ahead to be available through the U.K.’s National Health Service (NHS) for treating relapsing MS, at least in part of the country, is good news. But why has the decision taken…

Allison Wheeler is an unconventional heroine of a novel, but she found her way into my heart as I read A Million Ordinary Days by Judy Mollen Walters, a book being published today, March 14. Author Judy is also a Bionews Services columnist. She has Crohn’s disease and, writing…

Editor’s note: Our IBD columnist, Judy Walters, will have a new book out Tuesday in which the central character has multiple sclerosis. Here, she remembers how MS affected her own family during her childhood. I was only 10 when my grandmother died, but I remember so much about her. I remember…

Here is my Pick of the Week’s News, as published in Multiple Sclerosis News Today. ‘Liberation Therapy’ Is Useless, Costly, Potentially Dangerous, Study Finds At last, some positive research to debunk a supposed treatment that is not supported by any genuine repeatable research. To hear this ridiculous…

We all know, because we have heard it so many times, that MS is not the same for everyone — that no two people have exactly the same combination of symptoms. That got me…

Here’s my Pick of the Week’s News, as published in Multiple Sclerosis News Today. MS Organizations Join #MySupportHero Initiative to Help Patients Salute Those Who Care Oh, I can see me fitting in well here. To see what I mean, just take a look at two previous…

There is now less than a month until the U.S. Food and Drug Administration (FDA) is expected to approve Ocrevus, generic name ocrelizumab, for use as a therapy for multiple sclerosis. Clinical trials have shown Genentech’s drug to be a promising therapy for relapsing MS and, significantly,…

The ACTRIMS 2017 Forum is the source of my Pick of the Week’s News as published in Multiple Sclerosis News Today. There is Increased Evidence Linking Viruses to MS Risk This evidence goes some way toward justifying my view, previously published, about connections between viruses and MS. In particular,…

It was a trip, plain and simple, neither my leg giving way nor a fall. It was MS-related because it was directly caused by foot drop; the toe of my left shoe caught on the tiniest ridge at the bottom of…

Here`s my Pick of the Week’s News as published by Multiple Sclerosis News Today. Fitness Trainer and MS Patient, Dolly Stokes, Launches BFitLifestyles Website with Husband Looking after what you eat and exercising according to your abilities apparently can help alleviate symptoms of many chronic illnesses including…

Thoughts of love were brought to the forefront of many people’s minds on Valentine’s Day, which is widely celebrated by couples both young and not so young. They usually buy cards and enjoy romantic dinners. In our…

Here’s my Pick of the Week’s News as published in Multiple Sclerosis News Today. People with Chronic Diseases Support Obamacare More Than General Public, Survey Finds As everyone must know, throughout the world, politics in the U.S. has become extremely volatile and one of the focuses is…

Stress is like a light that turns on when you need it. But when you can’t turn it off, you run the risk of burnout, which can impact your health, according to the U.S. National MS Society. I often have said that I…

Obesity in early adolescence poses a risk for multiple sclerosis (MS) regardless of sex, and an earlier age at puberty also contributes to MS onset at younger ages, especially in overweight teenagers, a study reports. These findings were in the study, “Distinct…

Here’s my Pick of the Week’s News, as published by Multiple Sclerosis News Today. Clinical Trial Supports Stem Cell Transplants to Treat RMS Patients with High Disease Activity It’s no secret to readers of this column and, indeed, to the wider MS community, that I am convinced…

Continuous treatment with Gilenya (fingolimod) helps limit relapses and detectable lesions in multiple sclerosis (MS) patients, according to a three-year, follow-up study in Japan. The results confirm the findings of trials conducted in predominantly Caucasian populations. The findings were reported in the study, “Long-term efficacy and safety of fingolimod in…

Tecfidera (dimethyl fumarate or DMF) use by multiple sclerosis (MS) patients can result in liver injury and, in rare cases, even severe injury, a study found, leading its researchers to recommend that patients’ on this treatment be carefully monitored for signs of injury. The study, “…

Here is my Pick of the Week’s News, as published by Multiple Sclerosis News Today. Sense of Smell Impaired in Half of Multiple Sclerosis Patients in Study For very many years I have known that my sense of smell has not been as good as that considered normal…